Short Interest Analysis
As of the September 15, 2026, settlement date, Arcturus Therapeutics (ARCT) maintains a short interest of 5.5 million shares, representing 19.2% of its shares outstanding. While this remains a heavily shorted level—placing the stock in the top 7% of names tracked—the data indicates a cooling trend. Shorts have actively trimmed their exposure through three consecutive settlement periods, down from a peak of 21.5% of shares outstanding at the prior reading.
Market Dynamics
The days-to-cover ratio currently stands at 6.4, which remains elevated and suggests that any sudden positive catalyst could trigger a significant short squeeze. Despite the reduction in total short interest, the high days-to-cover metric indicates that liquidity remains a concern for those looking to exit positions quickly. The current borrow fee for ARCT is reported at 0.4%, suggesting that while the position is large, it is not currently experiencing extreme borrow scarcity or prohibitive costs for short sellers.
Signal data sourced from CurvedTrading. This post is an original analysis prepared by The Forensic Ledger from publicly available data. Not investment advice.
Not investment advice. This is original reporting and analysis prepared by The Forensic Ledger from publicly available data. Nothing here is a recommendation to buy, sell, or hold any security. Always consult the original source and a licensed professional. See our full disclaimer and source-citation policy.